Author

W. S. Liang

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:proteomics· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

W. P. D. Hendricks· 2 shared A. N. Karnezis· 1 shared A. Nazareno· 1 shared A. Sekulic· 1 shared B. C. Vanderhyden· 1 shared B. E. Weissman· 1 shared C. Sereduk· 1 shared D. G. Huntsman· 1 shared

Activity by Year

2017-2019 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

W. P. D. Hendricks

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Identification of frequent activating HER2 mutations in primary canine pulmonary adenocarcinoma

G. Lorch, K. Sivaprakasam, V. Zismann, N. Perdigones, T. Contente-Cuomo, A. Nazareno, S. Facista, S. Wong, K. Drenner, W. S. Liang, J. M. Amann, S. L. Sinicropi-Yao, M. J. Koenig, K. La Perle, T. G. Whitsett, , W. P. D. Hendricks

This study identifies HER2 mutations in canine pulmonary adenocarcinomas, finding V659E mutations in 38% of cases and their association with drug sensitivity.

bioRxiv · Feb 25, 2019 · PreprintCancer Biology

Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multi-kinase inhibition

J. D. Lang, W. P. D. Hendricks, H. Yin, J. Kiefer, P. Ramos, R. Sharma, P. Pirrotte, E. A. Raupach, C. Sereduk, N. Tang, W. S. Liang, M. Washington, S. J. Facista, V. L. Zismann, E. M. Cousins, , J. M. Trent

This paper identifies ponatinib as a potent treatment for SCCOHT by inhibiting multiple kinases in preclinical models.

bioRxiv · Jul 6, 2017Cancer Biology